Avalo Therapeutics AVTX EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's EPS (basic)?
- Avalo Therapeutics (AVTX) reported EPS (basic) of -$0.98 in Q1 2026.
- How has Avalo Therapeutics's EPS (basic) changed year-over-year?
- Avalo Therapeutics's EPS (basic) increased by 21.6% year-over-year, from -$1.25 to -$0.98.
- What is the long-term trend for Avalo Therapeutics's EPS (basic)?
- Over 2 years (2022 to 2025), Avalo Therapeutics's EPS (basic) has grown at a -92.7% compound annual growth rate (CAGR), from -$1,063.00 to -$5.73.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.